MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.
暂无分享,去创建一个
C. Creighton | Matthew L. Anderson | A. Lazar | R. Pollock | D. Lev | E. Demicco | S. Bolshakov | E. Young | Juehui Liu | A. Hoffman | Yechun Song | K. Bill | Pingyu Zhang | Tingsheng Peng | Dolores-López Terrada | G. Calin | Svetlana V. Bolshakov
[1] C. Sander,et al. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. , 2011, Cancer research.
[2] S. Aaronson,et al. High-frequency canonical Wnt activation in multiple sarcoma subtypes drives proliferation through a TCF/β-catenin target gene, CDC25A. , 2011, Cancer cell.
[3] W. Grizzle,et al. miR-155 promotes macroscopic tumor formation yet inhibits tumor dissemination from mammary fat pads to the lung by preventing EMT , 2011, Oncogene.
[4] A. Lazar,et al. An experimental model for the study of well differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors , 2010, Laboratory Investigation.
[5] C. Croce,et al. Targeting microRNAs in cancer: rationale, strategies and challenges , 2010, Nature Reviews Drug Discovery.
[6] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[7] Shuai Jiang,et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. , 2010, Cancer research.
[8] Domenico Coppola,et al. MicroRNA-155 Regulates Cell Survival, Growth, and Chemosensitivity by Targeting FOXO3a in Breast Cancer* , 2010, The Journal of Biological Chemistry.
[9] Muller Fabbri,et al. Modulation of mismatch repair and genomic stability by miR-155 , 2010, Proceedings of the National Academy of Sciences.
[10] R. Nolo,et al. Regulation of NOTCH Signaling by Reciprocal Inhibition of HES1 and Deltex 1 and its Role in Osteosarcoma Invasiveness , 2010, Oncogene.
[11] H. Taubert,et al. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival , 2010, International journal of cancer.
[12] T. Hupp,et al. CK1α Plays a Central Role in Mediating MDM2 Control of p53 and E2F-1 Protein Stability , 2009, The Journal of Biological Chemistry.
[13] C. Croce,et al. Src homology 2 domain-containing inositol-5-phosphatase and CCAAT enhancer-binding protein beta are targeted by miR-155 in B cells of Emicro-MiR-155 transgenic mice. , 2009, Blood.
[14] Xi He,et al. Wnt/beta-catenin signaling: components, mechanisms, and diseases. , 2009, Developmental cell.
[15] M. Loda,et al. c‐Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme , 2009, The Journal of pathology.
[16] I. Faraoni,et al. miR-155 gene: a typical multifunctional microRNA. , 2009, Biochimica et biophysica acta.
[17] Wei-Lien Wang,et al. Clinical, Pathological, and Molecular Variables Predictive of Malignant Peripheral Nerve Sheath Tumor Outcome , 2009, Annals of surgery.
[18] Quan-sheng Zhu,et al. Combining PCI-24781, a Novel Histone Deacetylase Inhibitor, with Chemotherapy for the Treatment of Soft Tissue Sarcoma , 2009, Clinical Cancer Research.
[19] C. Langmead,et al. ANGIOPOIETIN-2, A REGULATOR OF VASCULAR PERMEABILITY IN INFLAMMATION IS ELEVATED IN SEVERE ACUTE PANCREATITIS AND IS ASSOCIATED WITH SYSTEMIC ORGAN FAILURE , 2008 .
[20] Qiong Shao,et al. MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.
[21] Domenico Coppola,et al. MicroRNA-155 Is Regulated by the Transforming Growth Factor β/Smad Pathway and Contributes to Epithelial Cell Plasticity by Targeting RhoA , 2008, Molecular and Cellular Biology.
[22] S. Le,et al. Aberrant Expression of Oncogenic and Tumor-Suppressive MicroRNAs in Cervical Cancer Is Required for Cancer Cell Growth , 2008, PloS one.
[23] G. Tseng,et al. MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. , 2008, The Journal of clinical endocrinology and metabolism.
[24] T O Nielsen,et al. MicroRNA expression signature of human sarcomas , 2008, Oncogene.
[25] Aadel A. Chaudhuri,et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder , 2008, The Journal of experimental medicine.
[26] Ladan Fazli,et al. Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development , 2007, Proceedings of the National Academy of Sciences.
[27] Margaret S. Ebert,et al. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells , 2007, Nature Methods.
[28] T. Davison,et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma , 2007, Oncogene.
[29] Molly Megraw,et al. miRGen: a database for the study of animal microRNA genomic organization and function , 2006, Nucleic Acids Res..
[30] C. Croce,et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: A circuit diagram of differentiation control , 2006, Proceedings of the National Academy of Sciences.
[31] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[32] J. Coindre,et al. Retroperitoneal liposarcomas: Follow‐up analysis of dedifferentiation after clinicopathologic reexamination of 86 liposarcomas and malignant fibrous histiocytomas , 2006, Cancer.
[33] R. Stephens,et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. , 2006, Cancer cell.
[34] C. Croce,et al. A microRNA expression signature of human solid tumors defines cancer gene targets , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[35] Stefano Volinia,et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[36] Georgios Giamas,et al. The Role of the Casein Kinase 1 (CK1) Family in Different Signaling Pathways Linked to Cancer Development , 2005, Oncology Research and Treatment.
[37] C. Croce,et al. MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.
[38] H. Clevers,et al. Wnt signalling in stem cells and cancer , 2005, Nature.
[39] Wayne Tam,et al. Accumulation of miR-155 and BIC RNA in human B cell lymphomas. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[40] V. Ambros. The functions of animal microRNAs , 2004, Nature.
[41] M. Ballo,et al. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy , 2003, Cancer.
[42] Samuel Singer,et al. Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma , 2003, Annals of surgery.
[43] Tsuyoshi Saito,et al. β-Catenin Accumulation and Gene Mutation in Exon 3 in Dedifferentiated Liposarcoma and Malignant Fibrous Histiocytoma , 2002 .
[44] Matthias Mann,et al. Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway. , 2002, Genes & development.
[45] Axel Hoos,et al. Analysis of the Prognostic Significance of Microscopic Margins in 2,084 Localized Primary Adult Soft Tissue Sarcomas , 2002, Annals of surgery.
[46] F. Mertens,et al. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .
[47] L. Sobin,et al. World Health Organization classification of tumors , 2000, Cancer.
[48] F. Collin,et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors , 1999, Genes, chromosomes & cancer.
[49] R. Mladick,et al. Atypical lipoma, atypical intramuscular lipoma and well differentiated retroperitoneal liposarcoma , 1980 .
[50] R. Winkelmann,et al. Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma. A reappraisal of 30 cases formerly classified as well differentiated liposarcoma , 1979, Cancer.